The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Groundbreaking research exposes how diabetes damages kidneys, offering hope through early detection and innovative prevention ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Body-weight cycling, sometimes referred to as yo-yo dieting, may be harmful to the kidneys for people with type 1 diabetes, ...

Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...